Gefitinib-induced pyogenic granuloma in a patient with lung cancer

Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, th...

Full description

Saved in:
Bibliographic Details
Published inLung India Vol. 37; no. 1; pp. 71 - 72
Main Authors Sahoo, Satyajeet, Sirka, Chandra, Majumdar, Saroj, Mohapatra, Prasanta
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer India Pvt. Ltd 01.01.2020
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Adenocarcinoma
Antineoplastic agents
Binding sites
Cancer patients
Case Letters
Cetuximab
Epidermal growth factors
Fingers & toes
Gefitinib
Granuloma
Granulomas
Kinases
Lung cancer
Patients
Phenols (Class of compounds)
Signal transduction
Skin
Targeted cancer therapy
Tyrosine
India
Online AccessGet full text

Cover

More Information
Summary:Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, thereby inhibiting the activation of antiapoptotic signal transduction cascade, and results in uncontrolled cell proliferation. [...]the use of gefitinib has been increased in India, and physicians used to encounter such side effect frequently in patients receiving gefitinib.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_277_19